Managing the TME to improve the efficacy of cancer therapy.

Bilotta, Maria Teresa; Antignani, Antonella; Fitzgerald, David J

Bilotta, Maria Teresa; Antignani, Antonella; Fitzgerald, David J.

Afiliação

Bilotta MT; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Antignani A; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Fitzgerald DJ; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

Front Immunol ; 13: 954992, 2022.

Article em En | MEDLINE | ID: mdl-36341428

Assuntos

Antineoplásicos Imunológicos; Carcinoma Ductal Pancreático; Neoplasias Pancreáticas; Humanos; Microambiente Tumoral; Neoplasias Pancreáticas/patologia; Carcinoma Ductal Pancreático/patologia; Imunoterapia; Antineoplásicos Imunológicos/uso terapêutico

Palavras-chave

GBM - glioblastoma multiforme; Hodgkin (cHL); PDAC - pancreatic ductal adenocarcinoma; TME (tumor microenvironment); anti-cancer therapy; immunosuppression; immunotherapy combined therapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Antineoplásicos Imunológicos Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google